title: [Remarkably reduced tumor marker SCC levels by combined chemotherapy of paclitaxel and S-1 in two cases of advanced cervical cancer].
abstract: Case 1: A-35-year-old woman was diagnosed as cervical cancer Stage IIIb. When admitted to the hospital, her tumor marker SCC level was 50 ng/mL. Concurrent chemoradiation therapy was started on November, 2005. The SCC level was reduced by 0.9 ng/mL in February, 2006. In April, tumor recurrence was found by PET, and chemotherapy was restarted, but the SCC level was increased. In September, paclitaxel/S-1 therapy was performed, and the tumor markers were again reduced remarkably (SCC 9.8--> 1.3 ng/mL). Case 2: A-78-year-old woman was diagnosed as cervical cancer Stage IIIb. In August, 2004, concurrent chemoradiation therapy was started, and tumor markers were reduced (SCC 25.4--> 1.8 ng/mL). However, tumor markers were increased soon after the therapy. Chemotherapy was started, but it could not be maintained because of the side effects. In April, 2006, paclitaxel/S-1 therapy was performed, and the tumor markers were reduced remarkably (SCC 120--> 10 ng/mL). However, that therapy could also not be maintained because of the side effect. In July, she died of the cancer.
authors.affiliation: Dept. of Gynecology, Kushiro JRC Hospital.
authors.forename: Keiji
authors.initials: K
authors.lastname: Takagi
authors.forename: Hirokuni
authors.initials: H
authors.lastname: Kougo
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Aoyagi
authors.forename: Toshie
authors.initials: T
authors.lastname: Yonehara
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Minobe
authors.forename: Masaki
authors.initials: M
authors.lastname: Azuma
authors.forename: Tatsumi
authors.initials: T
authors.lastname: Yamaguchi
mesh_terms: D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000627:therapeutic use*; D017239:Paclitaxel / Q000627:therapeutic use*; D015843:Serpins / Q000097:blood*; D005641:Tegafur / Q000627:therapeutic use*; D017211:Treatment Failure; D002583:Uterine Cervical Neoplasms / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D004338:Drug Combinations; D015843:Serpins; C051072:squamous cell carcinoma-related antigen; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D017239:Paclitaxel